AZD8965 / AstraZeneca - LARVOL DELTA

Arginase inhibitor AZD8965: A novel therapeutic approach for idiopathic pulmonary fibrosis (ERS 2025) - "Moreover, in two Bleomycin-induced in- vivo mouse models of IPF, we successfully demonstrated the efficacy of AZD8965 to reduce lung ornithine levels (≥66%) and collagen synthesis (≥47%), resulting in an improvement in lung fibrosis endpoints. These findings support our hypothesis that reducing ornithine levels can effectively limit the availability of essential collagen building blocks. Consequently, our arginase inhibitor, AZD8965, emerges as a promising candidate for future monotherapy or combination therapies aimed at enhancing efficacy and tolerability in IPF treatment, with potential applicability extending beyond lung fibrosis."

Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • ARG1

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants (clinicaltrials.gov) - P1 | N=163 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open